A trial fibrillation (AF), the most common sustained cardiac arrhythmia, 1 carries an increased risk for ischemic stroke, heart failure (HF), and mortality. 2 The principles of AF management include rhythm control, rate control, and prevention of thromboembolism. Although AF is usually treated pharmacologically by targeting ventricular rate and the underlying abnormal rhythm, 1 the long-term efficacy of drug therapy may be limited. 3, 4 
AF-associated complications (death, stroke, and HF) in the patients who had no previous stroke or HF.
Methods

Data Source
The protocol for this study was approved by the National Taiwan University Hospital Research Ethics Committee (NTUH IRB 201211053RIC).
The Taiwan National Health Insurance database includes complete outpatient visits, hospital admissions, prescriptions, disease, and vital status for 99% of the country's population (≈23 million people). Several computerized claims data sets are linked with the National Death Registry through the use of birth dates and civil identification numbers unique to each beneficiary.
Study Population and Comparison Groups
Taiwan's consensus about performing RFA takes into account the following: (1) the stage of atrial disease (ie, AF type, left atrial size, AF history), (2) the presence and severity of underlying cardiovascular disease, (3) potential treatment alternatives (antiarrhythmic drugs, rate control), and (4) patients' values and preference. 7 Data were retrieved for all diagnostic codes for AF (the International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 427.31) from both inpatient or outpatient claims databases between January 1, 2003, and December 31, 2009 . Patients were included in the AF cohort analyses if they had ≥1 hospital admission, or ≥2 outpatient visits, with an AF diagnostic code within a year. Based on a prior validation study, this algorithm has a selection accuracy of 90%. 13, 14 Patients were excluded if they (1) were aged <20 or >100 years, (2) were of unknown sex, (3) had been previously hospitalized because of AF, and (4) had previous diagnosis of stroke or hospitalization for HF before study entry or RFA. The full cohort was then divided into those who received RFA and those who did not.
Services or procedure claims were used to identify patients who were hospitalized to receive RFA. The included cases were patients who had (1) a diagnosis of AF, (2) a procedural code for catheter ablation, and (3) a procedural code for trans-septal puncture, which together excluded other possibilities of ablation on right atrial flutter or atrioventricular junction. 15, 16 The date of hospitalization for RFA was defined as the index date. Patients who were hospitalized because of AF, stroke, or HF between AF diagnosis and the index date were also excluded. The follow-up started from the index date to death, disenrollment from national health insurance, or the study termination (December 31, 2010).
Because patients visiting different levels of hospitals might have distinct AF risk profiles, those who visited the same hospital within the same period of time were most likely to have similar baseline characteristics. Therefore, the 2 variables, hospitals and ±90 days of the RFA index date, were applied in the matching process to reduce selection bias. For each patient receiving RFA, ≤20 matched controls were selected. The patients who could not find any control in the same hospital within ±90 days were excluded (Figure) .
Covariate Ascertainment and Propensity Score Adjustment
Inpatient and outpatient diagnosis files and prescription records during the 12-month period before the index date were used to ascertain patients' history (ICD-9-CM codes provided in Table I in the Data  Supplement) , medication use ( Table II in the Data Supplement) , and medical resource utilization (Table 1) . Variables including age, sex, hypertension, diabetes mellitus, other medical history, medications, and medical resource utilization (Appendix in the Data Supplement) were incorporated into a nonparsimonious logistic regression model. The estimated probability of getting RFA, that is, the propensity score, was used as a single covariate for hazard adjustment in the subsequent survival analysis.
Outcome Definition
The primary outcome was mortality, obtained through a linkage to the National Death Registry. The secondary outcomes were stroke or hospitalization for HF, defined as having the ICD-9-CM diagnostic codes of 433 to 436 and 428, respectively, in the subsequent inpatient claims database. All medical expenses ≤6 years after the index date were compared in stroke-free patients from either group on a personto-person basis.
Statistical Analysis
Baseline characteristics were compared between patients with AF receiving RFA and matched controls. To evaluate the ability of the propensity score adjustment to control for confounding, the standardized mean differences before and after propensity score adjustment were compared.
The crude incidence rate and its 95% confidence interval (CI), for both primary and secondary outcomes, were estimated based on Poisson distribution. A Cox proportional hazards model, clustering on matched groups 17 and adjusted for baseline propensity score, was used to calculate the hazard ratio (HR), using matched patients with AF receiving no RFA as the reference group.
In fear that the difference in the death rates of the 2 groups, if any, might affect the hazard estimates for stroke or HF, an additional analysis using death as a competing risk was performed to evaluated the effect of RFA versus non-RFA on reducing stroke and HF. 18 To evaluate whether the effect of RFA may be modified by different patient characteristics, subgroup analyses were conducted stratified by age (≥75 versus <75 years), presence of hypertension, diabetes mellitus, ischemic heart disease, duration of AF (≥1 versus <1 year), and CHADS2 score (≥1 versus 0). A formal statistical test for the interaction term was performed accordingly. All statistical analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC). 
Results
During 2003 to 2009, a total of 218 041 patients had 1 inpatient or 2 outpatient diagnoses of AF. After exclusion, the full cohort (N=90 142) included 884 patients in the RFA group and 89 258 in the AF control groups. There are many differences in baseline characteristics between the 2 unselected groups ( Table 1 , left, also Table III in the Data Supplement, left). Patients with AF who received RFA were younger, predominantly male, less likely to have concomitant comorbidities, and less frequently prescribed a variety of medications except for class I/III antiarrhythmic drugs and calcium channel blockers. They used less medical resource, and their CHADS2 scores were lower. In the RFA group, 38 patients were further excluded because no match could be found in the same hospital within ±90 days. The final matched cohort included 846 patients in the RFA group and 11 324 in the AF control group (Figure) . The mean follow-up duration for the RFA and AF controls was 3.74 and 3.96 years (median: 3.45 and 3.82 years, respectively), respectively. During the follow-up, a total of 35 deaths in the RFA group and 1615 deaths in the AF control group were recorded. The crude mortality rate was 11.07 and 36.00 per 1000 person-years in the RFA and AF control groups, respectively. The incidence rates and crude HRs for stroke and HF are shown in Table 2 .
The baseline characteristics between the 2 treatment groups were still different in several aspects ( Table 1, right, also Table  III in the Data Supplement, middle). The propensity scores were 0.22±0.18 in the RFA group and 0.058±0.083 in the non-RFA controls (Appendix in the Data Supplement). However, the differences between the 2 groups decreased substantially and became highly comparable after adjusting for propensity scores ( Table III in the Data Supplement, right). The propensity score adjusted analysis showed that RFA was no longer associated with a reduction in mortality (HR, 0.88; 95% CI, 0.62-1.23; P=0.451), but was still associated with a 43% reduction in the hazard for stroke (HR, 0.57; 95% CI, 0.35-0.94; P=0.026). No significant decrease in the hazard for HF was found for those who received RFA; the adjusted HR was 0.78 (95% CI, 0.55-1.12; P=0.185; Table 2 ). In addition, if death was regarded as a competing risk, the HRs for stroke and HF between RFA and AF control groups remained basically unchanged (HR, 0.58; 95% CI, 0.35-0.95; P=0.029 for stroke and HR, 0.84; 95% CI, 0.54-1.14; P=0.199 for HF).
The subgroup analysis showed that the risk reduction in stroke was not affected by comorbidity (diabetes mellitus, Medical resource utilization analysis showed that the patients in the RFA group had more cardiology outpatient clinic visits and received more antiarrhythmic agents and anticoagulants but only in the first year. Such differences were not apparent in the following years. It seems unlikely that the reduction in stroke was attributed to the imbalance in anticoagulant use early in the post-RFA period. The per capita expense was higher in patients undergoing RFA, especially in the first year (Table 3 ).
Discussion
The results of this nationwide cohort study showed that the RFA group had a reduced incidence of stroke but not that of death or HF during a 3.5-year follow-up in the patients with AF who did not have previous stroke or HF.
Patients with AF are at a high risk for stroke, primarily of cardioembolic origin. The Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study showed that the stroke rate was not significantly different between their rate control and rhythm control arms. 2 In contrast, the ATHENA (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) trial demonstrated that the stroke rate was reduced by dronedarone therapy despite similar anticoagulant use in both dronedarone and placebo groups. 19 The current results are consistent with the large propensitymatched analysis using the MarketScan Research Database, which showed that AF ablation was associated with a reduced risk of stroke with no associated significant difference in HF hospitalizations compared with antiarrhythmic drug therapy. 15 This consistent risk reduction in stroke is presumed attributable to restoration of sinus rhythm. 20, 21 However, selection bias is a potential concern. Patients selected for ablation might be healthier and more symptomatic than patients who were not selected. They might also be more likely to be under the care of arrhythmia specialists. Despite the meticulous matching and model adjustment to ensure the balance of baseline risks and medical resource utilization, some residual bias might still exist because of unmeasured covariates. 22 AF contributes to loss of atrial systole, left ventricular systolic dysfunction, and aggravation of mitral regurgitation. Thus, elimination of AF with RFA might reduce HF symptoms. 23 However, it was previously shown that the role of RFA in patients with HF and AF is limited. 15, 24 The current analysis excluded patients previously hospitalized for HF and did not show a reduction in subsequent hospitalization for HF.
A recent study conducted from a large healthcare database registering 4212 patients who underwent AF ablation and 16 848 age-/sex-matched controls with AF (but no ablation) showed that the 3-year mortality was 6.0% and 23.5%, respectively. 25 The discrepancy in patient numbers between the 2 groups and a selection process that loosely matched by age and sex suggested that the observed survival difference might be attributed in part to selection bias, that is, including more favorable cases in the RFA arm. 25 On the contrary, despite the meticulous propensity score adjustment and an extended follow-up, a significant risk reduction in overall mortality was not demonstrable in the our analysis. Therefore, it seems that the evidence currently available that RFA prolongs survival in patients with AF will remain equivocal until a fair comparison can be made in ongoing clinical trials. For example, the Catheter Ablation versus Antiarrhythmic Drugs for Atrial Fibrillation (CABANA) is currently in progress and is expected to provide long-term survival data in 2015. 26 One major strength of the current analysis is the calculation of medical resource utilization for ≤6 years. Although RFA posed a reduced risk for stroke in patients with AF, their medical expense was significantly increased in the first year after the procedure without a compensatory reduction in the following years. Because this calculation is primitive and does not account for the presumed quality of life factors for the stroke-free subjects and the incremental costs for the patients with stroke, a formal cost-effectiveness analysis should be conducted.
There are several limitations in this study. First, we focused on the role of RFA in the primary prevention of stroke and HF. Therefore, the patients who had had stroke or HF before RFA were excluded. We could not generalize the results to those patients aiming for secondary prevention. An advantage of this restriction was to avoid contamination of the diagnostic codes, which might be carried in the following years and misinterpreted as a new event after RFA. Because the patients with higher CHADS2 scores are associated with an increased risk of AF recurrence after RFA, 27 it is also difficult to speculate how the results might change among these patients with a higher risk of stroke. Second, because the data source was a nationally sponsored claims database, the immediate outcome or procedural success of RFA (eg, the percentage of successful sinus rhythm restorations) was not available. 16 Also, the AF recurrence could not be identified after the procedure until the patient was later hospitalized attributable to AF. 28, 29 Third, details on the AF history (ie, persistent versus paroxysmal and left atrial size) were not available in the claims database. Fourth, although it was reported that ablation was superior to antiarrhythmic drug treatment in improving quality of life scale, 30 quality of life was not measured. Finally, no match could be found for 4.3% of the RFA group from the same hospital within ±90 days of the RFA index date, thus the results may not be completely generalizable to the entire study population.
In conclusion, RFA did not statistically reduce mortality or the need for future hospitalization attributable to HF. Although a reduction in stroke in patients who had no previous stroke or HF is suggested, residual confounding attributable to unmeasured factors is still a concern. The nominal but nonsignificant improvement in mortality risks suggests the potential value of a even longer follow-up in future randomized trials of RFA for AF.
